Clinical Trial

A Study of MG-K10 Humanized Monoclonal Antibody Injection in Subjects With Atopic Dermatitis

Study acronym: MG-K10
Completed Phase 2
View on ClinicalTrials.gov →
Summary
This study is a multicenter, randomized, double-blind, parallel controlled phase II study. It is planned to include approximately 60 subjects with moderate to severe atopic dermatitis(AD) to evaluate the efficacy and safety of MG-K10 monotherapy in adult patients with moderate to severe AD, and to observe PK characteristics, PD effects and immunogenicity.
Protocol Amendment History 3 changes
critical Completed without a posted recruiting period 2026-08-04
notable Primary completion moved earlier: 2027-07-16 -> 2026-03-09 2026-08-04
minor Completion moved earlier: 2027-12-16 -> 2026-04-29 2026-08-04
Trial Details
NCT Number NCT07103174
Lead Sponsor Shanghai Mabgeek Biotech.Co.Ltd
Conditions Atopic Dermatitis (AD)
Enrollment 60 participants
Start Date 2025-06-30
Primary Completion 2026-03-09 (estimated)
Study Completion 2026-04-29 (estimated)
Updated on ClinicalTrials.gov 2026-08-03